Hints and tips:
Related Special Reports
...pharmaceutical ingredients (API) for hundreds of US and European drugmakers....
...Private equity groups Bain, Cinven, Carlyle and Permira have all acquired contract manufacturers or contract research organisations in recent years....
...The company is aiming to develop a wide range of drugs and use its manufacturing scale to stay ahead of pharmaceutical rivals seeking to profit from consumer “hype” for weight loss products, he added....
...Its latest results show a 6 per cent fall in sales in the first quarter of 2024, which the company attributed to the strength of the Swiss franc and declining sales of its Covid-19 treatment Ronapreve....
...Drugs companies issued 1,643 warnings of impending shortages in 2023, compared to 648 in 2020, the research found....
...Friday’s decision comes after the state of New Hampshire failed in its bid to receive FDA permission because it did not identify a pharmaceutical wholesaler which could deliver the drugs....
...The Indianapolis-based company has struck agreements with US government-backed manufacturer National Resilience and Italian producer BSP Pharmaceuticals for the filling and “finishing” of its injector pens...
...Developing new antibiotics is often unattractive for pharmaceutical companies, as research and development costs are high but their use is designed to be limited to reduce the risk of the product driving...
...IDA’s Lohan warned of erecting new “barriers within the research and development cycle of new treatments” and possibly delaying market access....
...This has led to western pharmaceutical regulators struggling to enforce oversight of Chinese manufacturers....
...AstraZeneca has acquired oncology biotech Fusion Pharmaceuticals for $2.4bn to build its expertise and challenge Swiss company Novartis in the developing field of a more targeted form of radiotherapy....
...During my research on people living with pain, I have heard the same stories again and again: healthcare professionals telling patients that their symptoms are “just part of being a woman”, and that, tacitly...
...make up the backbone of pharmaceutical care....
...The US Food and Drug Administration and the European Medicines Agency recommended suspension of ranitidine products and the FDA asked all manufacturers to withdraw their products based on the drug....
...The writer is chief executive of the British Generic Manufacturers Association (BGMA) The UK is now in a global competition for medicines....
...generics manufacturer said....
...Bristol Myers Squibb is working on contingency plans to “protect the continuity of supply” of medicine in preparation for draft US legislation seeking to restrict Chinese pharmaceutical companies over national...
...This created a surge in demand for lab monkeys, which regulators insist are important to prove the safety of drugs in early research because of their anatomical and behavioural similarities to humans, despite...
...According to a European Commission analysis of the world’s 2,500 highest spending companies in research and development published in 2023, 12 per cent of leading companies investing in health research are...
...But according to Holst, who has worked as a consultant for the company, it has struggled to develop small-molecule GLP-1 drugs, which are much easier and cheaper for manufacturers to produce at scale....
...“Early diagnosis needs to be connected to treatment or it is pointless,” said Nick James, professor at the UK Institute of Cancer Research and leader of the work on prostate cancer....
...In contrast, pharmaceutical companies raised just $160mn for antibiotic research, a decline over the decade. Commercial activity and research in antibiotics have been in decline since the 1980s....
...The acquisition of Cardior Pharmaceuticals will give Novo Nordisk a treatment for heart failure in mid-stage trials that targets the root causes of heart disease....
...The results will renew attention on the possible effectiveness of lixisenatide, which is made by French pharmaceutical group Sanofi, and other so-called GLP-1 drugs against neurodegenerative conditions....
...A dearth of career scientists and public funding risks undermining efforts to use technological breakthroughs to tackle the biggest health threats, the head of a leading international research organisation...
International Edition